

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/083,743	02/26/2002	Anabella Villalobos	PC10802A	2304
23913 75	590 _ 11/05/2002			
PFIZER INC			EXAMINER	
150 EAST 42ND STREET 5TH FLOOR - STOP 49		WANG, SHENGJUN		
NEW YORK, NY 10017-5612			ART UNIT	PAPER NUMBER
			1617	EXAMINER WANG, SHENGJUN ART UNIT PAPER NUMBER 1617
			DATE MAILED: 11/05/2002	5

Please find below and/or attached an Office communication concerning this application or proceeding.

.;		Application No.	Applicant(s)			
Office Action Summary		10/083,743	VILLALOBOS, ANABELLA			
		Examiner	Art Unit			
		Shengjun Wang	1617			
	The MAILING DATE of this communication app					
	Period for Reply					
THE N - Exter after - If the - If NO - Failur - Any rearne	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. Issions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period we to reply within the set or extended period for reply will, by statute, eply received by the Office later than three months after the mailing d patent term adjustment. See 37 CFR 1.704(b).	16(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).			
Status 1)	December to communication (a) filed on					
1)[Responsive to communication(s) filed on					
2a)□	· —	s action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Dispositi	on of Claims	•				
	Claim(s) 1-16 is/are pending in the application.					
	4a) Of the above claim(s) is/are withdraw	n from consideration.				
	Claim(s) is/are allowed.					
	Claim(s) is/are rejected.					
	Claim(s) is/are objected to.					
8) Claim(s) 1-16 are subject to restriction and/or election requirement.						
Application Papers						
9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.						
10/1		·				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
	☐ All b)☐ Some * c)☐ None of:					
1. Certified copies of the priority documents have been received.						
	2. Certified copies of the priority documents have been received in Application No					
Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
	14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).					
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
2) 🔲 Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal P	(PTO-413) Paper No(s) atent Application (PTO-152)			

Application/Control Number: 10/083,743 Page 2

Art Unit: 1617

DETAILED ACTION

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims1-12, drawn to a pharmaceutical composition, classified in class 514, subclass 233.2, 292, 300.
 - II. Claims 13-16, drawn to a method of treating cognitive disorder, classified in class514, subclass 233.2, 299, 300.
- 2. Inventions Group I and Group II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the process as claimed can be practiced with another materially different product such as Cognex.
- 3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

4. Claims 1-16 generic to a plurality of disclosed patentably distinct species comprising: A)
GABA alpha 5 receptor inhibitors; and B) second ingredient. Applicant is required under 35

Art Unit: 1617

U.S.C. 121 to elect a single disclosed species (a single compound from each group) from each of the above groups, even though this requirement is traversed.

Page 3

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shengjun Wang, Ph.D. whose telephone number is (703) 308-4554. The examiner can normally be reached on Monday-Friday from 8:30 to 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan, can be reached on (703) 305-1877. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Examiner

Shengjun Wang

November 1, 2002